Adaptive immunity to Anaplasma pathogens and immune dysregulation: Implications for bacterial persistence

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 35, Issue 3, 2012, Pages 241-252

  Brown, Wendy C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Anaplasma marginale; Anaplasma phagocytophilum; High antigen load; Persistent infection; T cell dysregulation

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 1BETA; MAJOR SURFACE PROTEIN 2; MAJOR SURFACE PROTEIN 3; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANAPLASMOSIS; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGENIC VARIATION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CYTOKINE RESPONSE; DISEASE TRANSMISSION; HUMAN; IMMUNE DYSREGULATION; IMMUNE EVASION; IMMUNIZATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGEN CLEARANCE; T CELL DEPLETION;

ADAPTIVE IMMUNITY; ANAPLASMA MARGINALE; ANAPLASMA PHAGOCYTOPHILUM; ANAPLASMOSIS; ANIMALS; ANTIGENIC VARIATION; ANTIGENS, BACTERIAL; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; EHRLICHIOSIS; ERYTHROCYTES; IMMUNE EVASION; INTERFERON-GAMMA; MACROPHAGE ACTIVATION; RUMINANTS;

ANAPLASMA; ANAPLASMA MARGINALE; ANAPLASMA PHAGOCYTOPHILUM; ANIMALIA; BACTERIA (MICROORGANISMS); BOS; CANIS FAMILIARIS; EQUIDAE; MAMMALIA;

EID: 84859719186     PISSN: 01479571     EISSN: 18781667     Source Type: Journal    
DOI: 10.1016/j.cimid.2011.12.002     Document Type: Article

References (123)

1. Rikihisa Y. Anaplasma phagocytophilum and Ehrlichia chaffeensis: subversive manipulators of host cells. Nat Rev Microbiol 2010, 8:328-339.
2. Dumler J.S., Barbet A.F., Bekker C.P., Dasch G.A., Palmer G.H., Ray S.C., et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001, 51:2145-2165.
3. Chen S.M., Dumler J.S., Bakken J.S., Walker D.H. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994, 32:589-595.
4. Dumler J.S., Choi K.S., Garcia-Garcia J.C., Barat N.S., Scorpio D.G., Garyu J.W., et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005, 11:1824-1834.
5. Klein M.B., Miller J.S., Nelson C.M., Goodman J.L. Primary bone marrow progenitors of both granulocytic and monocytic lineases are susceptible to infection with the agent of human granulocytic ehrlichiosis. J Infect Dis 1997, 176:1405-1409.
6. Herron M.J., Ericson M.E., Kurtti T.J., Munderloh U.G. The interactions of Anaplasma phagocytophilum, endothelial cells, and human neutrophils. Ann N Y Acad Sci 2005, 1063:374-382.
7. Granquist E.G., Stuen S., Crosy L., Lundgren A.M., Alleman A.R., Barbet A.F. Variant-specific and diminishing immune responses towards the highly variable MSP2(P44) outer membrane protein of Anaplasma phagocytophilum during persistent infection in lambs. Vet Immunol Immunopathol 2010, 133:117-124.
8. Scorpio D.G., Leutenegger C., Berger J., Barat N., Madigan J.E., Dumler J.S. Sequential analysis of Anaplasma phagocytophilum msp2 transcription in murine and equine models of human granulocytic anaplasmosis. Clin Vaccine Immunol 2008, 15:418-424.
9. Whist S.K., Storset A.K., Johansen G.M., Larsen H.J.S. Modulation of leukocyte populations and immune responses in sheep experimentally infected with Anaplasma (formerly Ehrlichia) phagocytophilum. Vet Immunol Immunopathol 2003, 94:163-175.
10. Woldehiwet Z. Immune evasion and immunosuppression by Anaplasma phagocytophilum, the causative agent of tick-borne fever of ruminants and human granulocytic anaplasmosis. Vet J 2008, 175:37-44.
11. Stuen S., Longbottom D. Treatment and control of chlamydial and rickettsial infections in sheep and goats. Vet Clin North Am Food Anim Pract 2011, 27:213-233.
12. Theiler A. Anaplasma marginale (gen. spec. nov.) The marginal points in the blood of cattle suffering from a specific disease. Report of the Government Veterinary Bacteriologist, 1908-1909 Transvaal, South Africa; 1910: p. 7-64.
13. Aubry P., Geale D.W. A review of bovine anaplosmsis. Transbound Emerg Dis 2010, 58:1-30.
14. Kocan K.M., de la Fuente J., Blouin E.F., Coetzee J.F., Ewing S.A. The natural history of Anaplasma marginale. Vet Parasitol 2010, 167:95-107.
15. Munderloh U.G., Lynch M.J., Herron M.J., Palmer A.T., Kurtti T.J., Nelson R.D., et al. Infection of endothelial cells with Anaplasma marginale and A. phagocytophilum. Vet Microbiol 2004, 101:53-64.
16. Carreño A.D., Alleman A.R., Barbet A.F., Palmer G.H., Noh S.M., Johnson C.M. In vivo endothelial cell infection by Anaplasma marginale. Vet Pathol 2007, 44:116-118.
17. Wamsley J.L., Alleman A.R., Johnson C.M., Barbet A.F., Abbott J.R. Investigation of endothelial cells as an in vivo nidus of Anaplasma marginale infection in cattle. Vet Microbiol 2011, 153:264-273.
18. Futse J.E., Ueti M.W., Knowles D.P., Palmer G.H. Transmission of Anaplasma marginale by Boophilus microplus: retention of vector competence in the absence of vector-pathogen interaction. J Clin Microbiol 2003, 41:3829-3834.
19. Palmer G.H., Bankhead T., Lukehart S.A. 'Nothing is permanent but change' - antigenic variation in persistent bacterial pathogens. Cell Microbiol 2009, 11:1697-1705.
20. + T lymphocyte response but sustained high IgG titers. Clin Vaccine Immunol 2010, 17:1881-1890.
21. + T-lymphocyte responses specific for Anaplasma marginale major surface protein-2 (MSP2) in MSP2 vaccinates following challenge with live A. marginale. J Immunol 2005, 174:6702-6715.
22. Dumler J.S., Bakken J.S. Human ehrlichioses: newly recognized infections transmitted by ticks. Annu Rev Med 1998, 49:201-213.
23. IJdo J.W., Zhang Y., Hodzic E., Magnarelli L.A., Wilson M.L., Telford S.R., et al. The early humoral response in human granulocytic ehrlichiosis. J Infect Dis 1997, 176:687-692.
24. Artursson K., Gunnarsson A., Wikström U.B., Engvall E.O. A serological and clinical follow-up in horses with confirmed equine granulocytic ehrlichiosis. Equine Vet J 1999, 31:473-477.
25. Dumler J.S., Trigiani E.R., Bakken J.S., Aguero-Rosenfeld M.E., Wormser G.P. Serum cytokine responses during acute human granulocytic ehrlichiosis. Clin Diagn Lab Immunol 2000, 7:6-8.
26. Kim H.Y., Mott J., Zhi N., Tajima T., Rikihisa Y. Cytokine gene expression by peripheral blood leukocytes in horses experimentally infected with Anaplasma phagocytophila. Clin Diagn Lab Immunol 2002, 9:1079-1084.
27. Webster K.A., Mitchell G.B. Use of counter immunoelectrophoresis in detection of antibodies to tickborne fever. Res Vet Sci 1988, 45:28-30.
28. Paxton E.A., Scott G.R. Detection of antibodies to the agent of tick-borne fever by indirect immunofluorescence. Vet Microbiol 1989, 21:133-138.
29. Martin M.E., Bunnell J.E., Dumler J.S. Pathology, immunohistology, and cytokine responses in early phases of human granulocytic ehrlichiosis in a murine model. J Infect Dis 2000, 181:374-378.
30. Sun W., Ijdo J.W., Telford S.R., Hodzic E., Zhang Y., Barthold S.W., et al. Immunization against the agent of human granulocytic ehrlichiosis in a murine model. J Clin Invest 1997, 100:3014-3018.
31. Akkoyunlu M., Fikrig E. Gamma interferon dominates the murine cytokine response to the agent of human granulocytic ehrlichiosis and helps to control the degree of early rickettsemia. Infect Immun 2000, 68:1827-1833.
32. Banerjee R., Anguita J., Fikrig E. Granulocytic ehrlichiosis in mice deficient in phagocyte oxidase or inducible nitric oxide synthase. Infect Immun 2000, 68:4361-4362.
33. Martin M., Caspersen K., Dumler J.S. Immunopathology and ehrlichial propagation are regulated by interferon-γ and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol 2001, 158:1881-1888.
34. Telford S.R., Dawson J.E., Katavolos P., Warner C.K., Kolbert C.P., Persing D.H. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc Natl Acad Sci U S A 1996, 93:6209-6214.
35. Bunnell J.E., Trigani E.R., Srinivas S.R., Dumler J.S. Development and distribution of pathologic lesions are related to immune status and tissue deposition of human granulocytic ehrlichiosis agent-infected cells in a murine model system. J Infect Dis 1999, 180:546-550.
36. von Loewenich F.D., Scorpio D.G., Reischl U., Dumler J.S., Bogdan C. Control of Anaplasma phagocytophilum, an obligate intracellular pathogen, in the absence of inducible nitric oxide synthase, phagocyte NADPH oxidase, tumor necrosis factor, Toll-like receptor (TLR)2 and TLR4, or the TLR adaptor molecule MyD88. Eur J Immunol 2004, 34:1789-1797.
37. Choi K.-S., Webb T., Oelke M., Scorpio D.G., Dumler J.S. Differential innate immune cell activation and proinflammatory response in Anaplasma phagocytophilum infection. Infect Immun 2007, 75:3124-3130.
38. + T cells, but is independent of Th1 cytokines and a wide spectrum of effector mechanisms. Eur J Immunol 2008, 38:3395-3410.
39. Scorpio D.G., von Loewenich F.D., Göbel H., Bogdan C., Dumler J.S. Innate immune responses to Anaplasma phagocytophilum contributes to hepatic injury. Clin Vaccine Immunol 2006, 13:806-809.
40. Palmer G.H., Rurangirwa F.R., Kocan K.M., Brown W.C. Molecular basis for vaccine development against the ehrlichial pathogen Anaplasma marginale. Parasitol Today 1999, 15:281-286.
41. Estes D.M., Closser N.M., Allen G.K. IFN-γ stimulates IgG2 production from bovine B cells costimulated with anti-μ and mitogen. Cell Immunol 1994, 154:287-295.
42. + T-lymphocyte clones specific for rhoptry associated protein-1 (RAP-1) of Babesia bigemina stimulate enhanced immunoglobulin G1 (IgG1) and IgG2 synthesis. Infect Immun 1999, 67:155-164.
43. Palmer G.H., Eid G., Barbet A.F., McGuire T.C., McElwain T.F. The immunoprotective Anaplasma marginale major surface protein-2 (MSP-2) is encoded by a polymorphic multigene family. Infect Immun 1994, 62:3808-3816.
44. Tebele N., McGuire T.C., Palmer G.H. Induction of protective immunity using Anaplasma marginale initial body membranes. Infect Immun 1991, 59:3199-3204.
45. Lopez J.E., Siems W.F., Brayton K.A., Palmer G.H., McGuire T.C., Brown W.C. Identification of novel antigenic proteins in a complex Anaplasma marginale outer membrane immunogen by mass spectrometry and genomic mapping. Infect Immun 2005, 73:8109-8118.
46. Palmer G.H., McGuire T.C. Immune serum against Anaplasma marginale initial bodies neutralizes infectivity for cattle. J Immunol 1984, 133:1010-1015.
47. Palmer G.H., McElwain T.F. Molecular basis for vaccine development against anaplasmosis and babesiosis. Vet Parasitol 1995, 57:233-253.
48. Eid G., French D.M., Lundgren A.M., Barbet A.F., McElwain T.F., Palmer G.H. Expression of major surface protein 2 antigenic variants during acute Anaplasma marginale rickettsemia. Infect Immun 1996, 64:836-841.
49. French D., Brown W.C., Palmer G.H. Emergence of Anaplasma marginale antigenic variants during persistent rickettsemia. Infect Immun 1999, 67:5834-5840.
50. Gale K.R., Leatch G., Gartside M., Dimmock C.M. Anaplasma marginale: failure of sera from immune cattle to confer protection in passive-transfer experiments. Parasitol Res 1992, 78:410-415.
51. Buening G.M. Cell-mediated immune response in anaplasmosis as measured by a micro cell-mediated cytotoxicity assay and leukocyte migration inhibition test. Am J Vet Res 1976, 34:1215-1218.
52. Carson C.A., Sells D.M., Ristic M. Cell mediated immunity in bovine anaplasmosis and correlation with protection induced by vaccination. Vet Parasitol 1976, 2:75-81.
53. Wyatt C.R., Davis W.C., Knowles D.P., Goff W.L., Palmer G.H., McGuire T.C. Effect of intraerythrocyte Anaplasma marginale of soluble factors from infected calf blood mononuclear cells. Infect Immun 1996, 64:4846-4849.
54. Gale K.R., Leatch G., Dimmock C.M., Wood P.R. Anaplasma marginale: effect of the treatment of cattle with an interferon γ-neutralizing monoclonal antibody or the nitric oxide synthetase inhibitor aminoguanidine on the course of infection. Parasite Immunol 1997, 19:411-417.
55. Gale K.R., Gartside M.G., Dimmock C.M., Zakrzewski H., Leatch G. Peripheral blood lymphocyte proliferative responses in cattle infected or vaccinated with Anaplasma marginale. Parasitol Res 1996, 82:551-562.
56. + T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge. Infect Immun 1998, 66:5406-5413.
57. Palmer G.H., Munodzana D., Tebele N., Ushe T., McElwain T.F. Heterologous strain challenge of cattle immunized with Anaplasma marginale outer membranes. Vet Immunol Immunopathol 1994, 42:265-273.
58. Noh S.M., Zhuang Y., Futse J.E., Brown W.C., Brayton K.A., Palmer G.H. The immunization-induced response to the Anaplasma marginale major surface protein 2 and its association with protective immunity. Vaccine 2010, 28:3471-3477.
59. McGuire T.C., Musoke A.J., Kurtti T. Functional properties of bovine IgG1 and IgG2: interaction with complement, macrophages, neutrophils, and skin. Immunology 1979, 38:249-256.
60. Lopez J.E., Palmer G.H., Brayton K.A., Dark M.J., Leach S.E., Brown W.C. Immunogenicity of Anaplasma marginale type IV secretion system proteins in a protective outer membrane vaccine. Infect Immun 2007, 75:2333-2342.
61. Lopez J.E., Beare P.A., Heinzen R.A., Norimine J., Lahmers K.K., Palmer G.H., et al. High-throughput identification of T-lymphocyte antigens from Anaplasma marginale expressed using in vitro transcription and translation. J Immunol Methods 2008, 332:129-141.
62. Sutten E.L., Norimine J., Beare P.A., Heinzen R.A., Lopez J.E., Morse K., et al. Anaplasma marginale type IV secretion system proteins VirB2, VirB7 VirB11, and VirD4 are immunogenic components of a protective bacterial membrane vaccine. Infect Immun 2010, 78:1314-1325.
63. Morse K., Norimine J., Palmer G.H., Sutten E.L., Baszler T.V., Brown W.C. Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale. Infect Immun 2012, 80(1):215-227.
64. Noh SM, Brown WC. Adaptive immune responses to infection and opportunities for vaccine development (Anaplasmataceae). In: Palmer GH, Azad AF, editors. Intracellular pathogens: Rickettsiales. Washington, DC: ASM Press, 2012, in press.
65. Lin M., Rikihisa Y. Ehrlichia chaffeensis and Anaplasma phagocytophilum lack genes for lipid A biosynthesis and incorporate cholesterol for their survival. Infect Immun 2003, 71:5324-5331.
66. Brayton K.A., Kappmeyer L.S., Herndon D.R., Dark M.J., Tibbals D.L., Palmer G.H., et al. Complete genome sequencing of Anaplasma marginale reveals that the surface is skewed to two superfamilies of outer membrane proteins. Proc Natl Acad Sci U S A 2005, 102:844-849.
67. Ulevitch R.J., Mathison J.C., da Silva Correia J. Innate immune responses during infection. Vaccine 2004, 22(Suppl. 1):S25-S30.
68. Sorbara M.T., Philpott D.J. Peptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis. Immunol Rev 2011, 243:40-60.
69. Carlyon J.A., Fikrig E. Mechanisms of evasion of neutrophil killing by Anaplasma phagocytophilum. Curr Opin Hematol 2006, 13:28-33.
70. Rikihisa Y. Molecular events in cellular invasion by Ehrlichia chaffeensis and Anaplasma phagocytophilum. Vet Parasitol 2010, 167:155-166.
71. Gillespie J.J., Brayton K.A., Williams K.P., Quevo Diaz M.A., Brown W.C., Azad A.F., et al. Phylogenomics reveals a diverse Rickettsiales type IV secretion system. Infect Immun 2010, 78:1809-1823.
72. Rikihisa Y., Lin M. Anaplasma phagocytophilum and Ehrlichia chaffeensis type IV secretion and Ank proteins. Curr Opin Microbiol 2010, 13:59-66.
73. Rikihisa Y. Type IV secretion in the obligatory intracellular bacterium Anaplasma phagocytophilum. Cell Microbiol 2010, 12:1213-1221.
74. Lin M., den Dulk-Ras A., Hooykaas P.J., Rikihisa Y. Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection. Cell Microbiol 2007, 9:2644-2657.
75. Niu H., Kozjak-Pavlovic V., Rudel T., Rikihisa Y. Anaplasma phagocytophilum Ats-1 is imported into host cell mitochondria and interferes with apoptosis induction. PLoS Pathog 2010, 6:e1000774.
76. Noh S., Brayton K.A., Brown W.C., Norimine J., Munske G.R., Davitt C.M., et al. Composition of the surface proteome of Anaplasma marginale and its role in protective immunity induced by outer membrane immunization. Infect Immun 2008, 76:2219-2226.
77. Lockwood S., Voth D.E., Brayton K.A., Beare P.A., Brown W.C., Heinzen R.A., et al. Identification of Anaplasma marginale Type IV secretion system effector proteins. PLoS One 2011, 6(11):e27724.
78. Barbet A.F., Lundgren A., Yi J., Rurangirwa F.R., Palmer G.H. Antigenic variation of the ehrlichia Anaplasma marginale by expression of MSP2 sequence mosaics. Infect Immun 2000, 68:6133-6138.
79. Barbet A.F., Yi J., Lundgren A., McEwen B.R., Blouin E.F., Kocan K.M. Antigenic variation of Anaplasma marginale: major surface protein 2 diversity during cyclic transmission between ticks and cattle. Infect Immun 2001, 69:3057-3066.
80. Brayton K.A., Palmer G.H., Lundgren A., Yi J., Barbet A.F. Antigenic variation of Anaplasma marginale msp2 occurs by combinatorial gene conversion. Mol Microbiol 2002, 43:1151-1159.
81. Brayton K.A., Meeus P.F., Barbet A.F., Palmer G.H. Simultaneous variation of the immunodominant outer membrane proteins MSP2 and MSP3, during Anaplasma marginale persistence in vivo. Infect Immun 2003, 71:6627-6632.
82. Meeus P.F., Brayton K.A., Palmer G.H., Barbet A.F. Conservation of a gene conversion mechanism in two distantly related paralogues of Anaplasma marginale. Mol Microbiol 2003, 47:633-643.
83. Barbet A.F., Meeus P.F., Belanger M., Bowie M.V., Yi J., Lundgren A.M., et al. Expression of multiple outer membrane protein sequence variants from a single genomic locus of Anaplasma phagocytophilum. Infect Immun 2003, 71:1706-1718.
84. Zhi N., Ohashi N., Rikihisa Y., Horowitz H.W., Wormser G.P., Hechemy K. Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis. J Clin Microbiol 1998, 36:1666-1673.
85. Murphy C.I., Storey J.R., Recchia J., Doros-Richert L.A., Gingrich-Baker C., Munroe K., et al. Major antigenic proteins of the agent of human granulocytic ehrlichiosis are encoded by members of a multigene family. Infect Immun 1998, 66:3711-3718.
86. + T cell epitopes are evenly distributed in conserved and hypervariable regions (HVR), whereas linear B cell epitopes are predominantly located in the HVR. Infect Immun 2004, 72:1096-1106.
87. Zhuang Y., Futse J.E., Brown W.C., Brayton K.A., Palmer G.H. Maintenance of antibody to pathogen epitopes generated by segmental gene conversion is highly dynamic during long-term persistent infection. Infect Immun 2007, 75:5185-5190.
88. Granquist E.G., Stuen S., Lundgren A.M., Braten M., Barbet A.F. Outer membrane protein sequence variation in lambs experimentally infected with Anaplasma phagocytophilum. Infect Immun 2008, 76:120-126.
89. IJdo J.W., Wu C., Telford S.R., Fikrig E. Differential expression of the p44 gene family in the agent of human granulocytic ehrlichiosis. Infect Immun 2002, 70:5295-5298.
90. + T lymphocyte epitopes that elicit variant-specific proliferative and IFN-γ responses in MSP2 vaccinates. J Immunol 2003, 170:3790-3798.
91. Sloan-Lancanster J., Allen P.M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996, 14:1-27.
92. Plebanski M., Lee E.A., Hill A.V. Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology 1997, 115:S55-S66.
93. McMichael A. T cell responses and viral escape. Cell 1998, 93:673-676.
94. Carlyon J.A., Chan W.T., Galán J., Roos D., Fikrig E. Repression of rac2 mRNA expression by Anaplasma phagocytophila is essential to the inhibition of superoxide production and bacterial proliferation. J Immunol 2002, 169:7009-7018.
95. Whist S.K., Storset A.K., Larsen H.J.S. Functions of neutrophils in sheep experimentally infected with Ehrlichia phagocytophila. Vet Immunol Immunopathol 2002, 86:183-193.
96. Borjesson D.L., Kobayashi S.D., Whitney A.R., Voich J.M., Agrue C.M., DeLeo F.R. Insights into pathogen immune evasion mechanisms: Anaplasma phagocytophilum fails to induce an apoptosis differentiation program in human neutrophils. J Immunol 2005, 174:6364-6372.
97. + T cells following infection represents a strategy of immune evasion and persistence for Anaplasma marginale. J Immunol 2008, 181:7759-7769.
98. Mebius R.E., Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005, 5:606-616.
99. + T lymphocytes using bovine DRB3*1101 and DRB3*1201 tetramers. Immunogenetics 2006, 58:726-739.
100. + T lymphocytes recognize conserved immunodominant epitopes of Anaplasma marginale major surface protein 1a. Infect Immun 2002, 70:5521-5532.
101. Mwangi W., Brown W.C., Splitter G.A., Davies C.J., Howard C.J., Hope J.C., et al. A DNA vaccine construct incorporating intercellular trafficking and intracellular targeting motifs effectively primes and induces memory B and T cell responses in outbred animals. Clin Vaccine Immunol 2007, 14:304-311.
102. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007, 7:875-888.
103. Reinbold J.B., Coetzee J.F., Hollis L.C., Nickell J.S., Reigel C., Olson K.C., et al. The efficacy of three chlortetracycline regimens in the treatment of persistent Anaplasma marginale infection. Vet Microbiol 2010, 145:69-75.
104. + T cell contraction during pathogen challenge. Immunol Rev 2010, 236:110-124.
105. Klenerman P., Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005, 6:873-879.
106. Seder R.A., Darrah P.A., Roederer M. T cell quality in memory and protection: implications for vaccine development. Nat Rev Microbiol 2008, 8:247-258.
107. Dalton D.K., Haynes L., Chu C.-Q., Swain S.L., Wittmer S. Interferon γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000, 192:117-122.
108. + T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptosis signals. J Immunol 2007, 179:939-949.
109. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010, 22:223-230.
110. + T cells endowed with proliferative capacity. J Exp Med 2003, 198:1902-1922.
111. Struik S.S., Riley E.M. Does malaria suffer from lack of memory?. Immunol Rev 2004, 201:268-290.
112. + T cells in malaria infection. J Exp Med 2002, 195:881-892.
113. Helmby H.G., Jonsson G., Troye-Blomberg M. Cellular changes and apoptosis in the spleens and peripheral blood of mice infected with blood-stage Plasmodium chabaudi chabaudi AS. Infect Immun 2000, 68:1485-1490.
114. + T cells undergo extensive apoptosis during a Plasmodium chabaudi chabaudi AS infection. Parasite Immunol 2001, 23:617-626.
115. Freitas do Rosário A.P., Muxel S.M., Rodríguez-Málaga S.M., Sardinha L.R., Zago C.A., Castillo-Méndez S.I., et al. Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. J Immunol 2008, 181:8344-8355.
116. + T cells and is overcome by IL-2. Eur J Immunol 2002, 32:634-643.
117. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and disease progression. Nature 2006, 443:350-354.
118. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398-11403.
119. + T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
120. Hafler D.A., Kuchroo V. TIMs: central regulators of immune responses. J Exp Med 2008, 205:2699-2701.
121. Jones R.B., Ndhlovu L.C., Barbour J., Sheth P.M., Jha A.R., Long B.R., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008, 205:2763-2779.
122. + T cells. J Virol 2009, 83:9122-9130.
123. + T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol 2009, 6:35-43.